Experimental compound increased early rhythm recurrence after an atrial fibrillation procedure
In a randomized pilot trial around an atrial fibrillation procedure, the experimental compound produced higher early recurrence odds than placebo. After treatment stopped, follow-up showed no detected recurrence difference.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
For people undergoing atrial fibrillation ablation, the experimental compound 2-HOBA increased the odds of rhythm recurrence during early monitoring compared with placebo. The measured blood marker did not differ between groups. After treatment ended, no recurrence difference was detected during extended follow-up; this result does not establish equivalence or apply to every atrial fibrillation setting.
This pilot concerned the period around ablation, and the abstract does not give the sample size or absolute recurrence rates. The authors explicitly leave generalizability to other atrial fibrillation settings unresolved.
What researchers found
Atrial fibrillation recurrence after ablation
2-HOBA versus placebo during 28-day monitoring: adjusted odds ratio 3.65 (95% CI 1.31–10.16). This compares odds, rather than absolute recurrence probabilities.
How recurrence was monitored
Participants used smartwatch recordings of heart electrical activity to detect recurrence after the procedure. The central result therefore concerns documented return of the rhythm disorder, rather than a change in symptoms or a blood-marker measurement.
The marker did not differ
Blood measurements of isolevuglandins, the compound's intended target, showed no group difference. That result does not explain why recurrence increased. The abstract reports the clinical and laboratory findings separately without establishing the mechanism behind the unexpected recurrence result.
The original publication
2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial.
Yoneda ZT, O'Neill M, Crawford DM et al.
Circ Arrhythm Electrophysiol · 2025
- PubMed ID
- 40709466
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.